A 55-year-old female consulted the pulmonary medicine department with chief complaints of obstructive pneumonia, chest pain, dyspnea, and cough. Computed tomography (CT)-guided biopsy of the left lung mass showed tissue consistent with Grade 2 neuroendocrine tumor (NET) \[[Figure 1a](#F1){ref-type="fig"}\] which was immunopositive for chromogranin \[[Figure 1b](#F1){ref-type="fig"}\], synaptophysin \[[Figure 1c](#F1){ref-type="fig"}\], and cytokeratin \[[Figure 1d](#F1){ref-type="fig"}\]. She was subsequently referred to the nuclear medicine department for whole-body ^68^Ga-DOTANOC positron emission tomography/computed tomography (PET/CT) and ^18^F-fluorodeoxyglucose (FDG) PET/CT scans to detect the extent of disease. Grade-2 NET lung detected on biopsy (primary) showed positive uptake on both ^68^Ga-DOTANOC PET/CT \[arrow, [Figure 1e](#F1){ref-type="fig"}\] and ^18^F-FDG PET/CT \[arrow, [Figure 1f](#F1){ref-type="fig"}\] scans. However, multiple metastatic lesions in the liver showed no somatostatin receptor expression as evidenced by negative ^68^Ga-DOTANOC PET/CT \[arrow, Figure [1g](#F1){ref-type="fig"} and [i](#F1){ref-type="fig"}\] but showed avid lesions on ^18^F-FDG PET/CT \[arrow, Figure [1h](#F1){ref-type="fig"} and [j](#F1){ref-type="fig"}\], proving it to be as poorly differentiated metastases. Similarly, another solitary metastatic lesion noted in the pancreas was positive on ^68^Ga-DOTANOC PET/CT scan \[arrow, [Figure 1k](#F1){ref-type="fig"}\] but showed no radiotracer uptake on ^18^F-FDG PET/CT \[[Figure 1l](#F1){ref-type="fig"}\], implying it to be a well-differentiated metastatic lesion. Another lesion noted in the spleen was positive on ^18^F-FDG PET/CT \[arrow, [Figure 1l](#F1){ref-type="fig"}\], but no tracer uptake was observed on ^68^Ga-DOTANOC PET/CT scan \[[Figure 1k](#F1){ref-type="fig"}\], consistent with poorly differentiated uptake pattern. Multiple bone metastases were positive on ^68^Ga-DOTANOC PET/CT \[arrow, [Figure 1m](#F1){ref-type="fig"}\] but negative on ^18^F-FDG PET/CT scan \[[Figure 1n](#F1){ref-type="fig"}\], which implied it to be well differentiated. Figure [1o](#F1){ref-type="fig"} and [p](#F1){ref-type="fig"} depict the maximum intensity projection images of ^68^Ga-DOTANOC PET/CT \[[Figure 1o](#F1){ref-type="fig"}\] and ^18^F-FDG PET/CT \[[Figure 1p](#F1){ref-type="fig"}\]. Bronchial carcinoids are rare well-differentiated NET subclassified into typical and atypical carcinoids.\[[@ref1]\] Using ^68^Ga-DOTANOC PET/CT and ^18^F-FDG PET/CT scan, we can differentiate between various grades of NETs.\[[@ref2]\] ^68^Ga-DOTANOC PET/CT is the initial evaluation of choice for detection of primary sites for patients with metastatic NETs of unknown origin as well as well-differentiated NETs.\[[@ref3]\] ^18^F-FDG PET/CT also has an important role in managing patients with aggressive and high-grade NETs owing to its high prognostic value, and further treatment change is based on this poor differentiation of the tumor. ^68^Ga-DOTANOC PET-CT alone at the best is helpful in delineating disease extent. The evaluation of glycolytic metabolism by ^18^F-FDG is potentially useful in identifying high-risk patients with aggressive neuroendocrine disease associated with a poor outcome.\[[@ref4]\]^68^-Ga DOTANOC PET/CT and ^18^F-FDG PET/CT have a complementary role in patients who have aggressive disease as it helps in demonstrating the total disease burden and stratify them to proper therapeutic groups.\[[@ref5]\] Dual-tracer imaging with ^68^-Ga-DOTANOC and ^18^-F-FDG PET-CT can have a prognostic value in metastatic NETs as positive somatostatin receptor expression with negative FDG uptake exhibits a longer progression-free survival.\[[@ref6]\] In such patients, somatostatin analogs can be used as first-line agent, while high FDG uptake warrants treatment with chemotherapy.\[[@ref7][@ref8]\] In this case, splenic lesion was positive on ^18^-F FDG PET/CT and negative on ^68^Ga DOTANOC PET/CT. One must be careful in reporting splenic lesion on ^68^Ga-DOTANOC PET/CT as such lesions could be missed due to high physiological splenic DOTANOC uptake. This case highlights the fact that in a metastatic NET, various grades of differentiation can be present at a given point of time. Hence, imaging with ^18^-F-FDG PET/CT and ^68^-Ga-DOTANOC PET/CT can give a complete picture about the disease status and should be used in routine for better management of patients.

![(a-d) Grade II neuroendocrine tumor immunopositive for chromogranin, synaptophysin cytokeratin, (e and f) neuroendocrine tumor Grade II lung, both DOTANOC and fluorodeoxyglucose positive, (g and i) DOTANOC-negative liver lesions, (h and j) fluorodeoxyglucose-positive liver lesions, (k) DOTANOC-positive pancreas lesion and DOTANOC-negative spleen lesion, (l) fluorodeoxyglucose-negative pancreas lesion and fluorodeoxyglucose-positive spleen lesion, (m) DOTANOC-positive bone metastases, (n) fluorodeoxyglucose-negative bone metastases, (o) maximum intensity projection image of ^68^-Ga DOTANOC positron emission tomography/computed tomography, (p) maximum intensity projection image of ^18^-F-fluorodeoxyglucose positron emission tomography/computed tomography](IJNM-34-260-g001){#F1}
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